Across Europe, by 30 June 2018, the pharmaceutical industry will disclose payments made to health professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. Bringing greater transparency to this, already well-regulated, vital relationship is about strengthening the basis for collaboration in the future. Industry is being proactive, based on its commitment to this relationship. Collaboration between industry and health professionals benefits patients. It is a relationship that has delivered numerous innovative medicines and changed the way many diseases impact on our lives. Industry and health professionals collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway. Society has increasingly high expectations for transparency, none more so than in healthcare. As a member of EFPIA, Pierre Fabre group want to ensure we meet those expectations complying with EFPIA Disclosure Code.
About the EFPIA Disclosure Code
The EFPIA Disclosure Code is a code of conduct that requires all EFPIA member companies and companies that are members of EFPIA member associations to disclose transfers of value to Healthcare Professionals (HCPs) and healthcare organizations (HCOs).
The first disclosures were made by 30 June 2016, for payments made in 2015. For Pierre Fabre affiliates in Europe, Russia, this information will be published on a public platform, which could be on a central national platform, combing data from different companies, on each affiliate company’s own website or, on the company’s corporate website when affiliate doesn’t have its own website (see after for these public disclosures).
Disclosure Methodology Pierre Fabre Pharmaceuticals 2017
Disclosure Methodology Pierre Fabre Pharmaceuticals 2016
Austria
Belgium
Bulgaria
- Public disclosure 2016
- No Transfer of Value in 2017
Czech Republic
Denmark
Estonia
- No Transfer of Value in 2016
- Public disclosure 2017
Finland
France
Germany
Greece
Hungary
- Public disclosure 2016
- No Transfer of Value in 2017
Italy
Ireland
Lithuania
Poland
- Public disclosure HCP 2015
- Public disclosure HCO 2015
- Public Disclosure HCP 2016
- Public Disclosure HCO 2016
- Public Disclosure R&D 2016
- Public disclosure HCP 2017
- Public disclosure HCO 2017
- Public disclosure R&D 2017
Portugal
Romania
Russia
Slovak republic
Spain
Sweden
Switzerland
- Public disclosure Pierre Fabre (Suisse) SA 2015
- Public disclosure Pierre Fabre Pharma AG 2015
- Public disclosure Pierre Fabre Pharma AGS 2016
- Public disclosure 2017
Ukraine
- No Transfer of Value in 2016
- Public disclosure 2017
United Kingdom
Following European legislation on data privacy, recipients of published transfers of value have a right to access and correct personal data concerning them, which is exercisable by email.
For further information about the EFPIA disclosure code